Back to Search
Start Over
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
- Source :
- HIV Medicine, Vol. 19, No 2 (2018) pp. 102-117, EuroSIDA Study Group 2018, ' Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens ', HIV Medicine, vol. 19, no. 2, pp. 102-117 . https://doi.org/10.1111/hiv.12557, HIV MEDICINE, Cozzi-Lepri, A, Zangerle, R, Machala, L, Zilmer, K, Ristola, M, Pradier, C, Kirk, O, Sambatakou, H, Fätkenheuer, G, Yust, I, Schmid, P, Gottfredsson, M, Khromova, I, Jilich, D, Flisiak, R, Smidt, J, Rozentale, B, Radoi, R, Losso, M H, Lundgren, J D, Mocroft, A & Eurosida Study Group 2018, ' Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens ', HIV Medicine, vol. 19, no. 2, pp. 102-117 . https://doi.org/10.1111/hiv.12557, HIV medicine, 19(2), 102-117. Wiley-Blackwell, HIV Medicine
- Publication Year :
- 2017
- Publisher :
- Wiley, 2017.
-
Abstract
- Publisher's version (útgefin grein)<br />Objectives There are currently few data on the long‐term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. Methods The EuroSIDA cohort was divided into three groups: those starting RAL‐based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. Results The RAL cohort included 1470 individuals [with 4058 person‐years of follow‐up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non‐AIDS‐related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention‐to‐treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65–1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76–1.72 for RALvs. CONC). Conclusions We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.<br />EuroSIDA was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no. 260694. Current support includes unrestricted grants from Bristol‐Myers Squibb, Gilead, GlaxoSmithKline LLC, Janssen R&D, Merck and Co. Inc. and Pfizer Inc. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). The study is also supported by a grant (grant number DNRF126) from the Danish National Research Foundation.
- Subjects :
- Male
0301 basic medicine
observational treatment comparison
HIV Infections
Rate ratio
propensity scores
0302 clinical medicine
Antiretroviral Therapy, Highly Active
Neoplasms
Medicine and Health Sciences
Risk of mortality
AIDS-DEFINING
Pharmacology (medical)
Prospective Studies
030212 general & internal medicine
Prospective cohort study
Original Research
EXPERIENCED
ddc:616
IMMUNODEFICIENCY
Incidence
Health Policy
Incidence (epidemiology)
risk of cancer
Middle Aged
3. Good health
Infectious Diseases
Anti-Retroviral Agents
SAFETY
EXPERIENCED PATIENTS
Cohort
AIDS-DEFINING CANCERS
Female
Historical Cohort
medicine.drug
Adult
Alnæmi
medicine.medical_specialty
animal structures
CANCERS
HIV INTEGRASE INHIBITORS
030106 microbiology
Antiretroviral Therapy
survival
Risk Assessment
HIV-1-INFECTED PATIENTS
MALIGNANCIES
03 medical and health sciences
Lyf
Raltegravir Potassium
Internal medicine
PATIENTS
medicine
Humans
COHORT
Highly Active
propensity score
Krabbamein
OPTIMIZED BACKGROUND THERAPY
business.industry
observational treatment
Raltegravir
Survival Analysis
Odds ratio
INFECTED INDIVIDUALS
comparison
3121 General medicine, internal medicine and other clinical medicine
business
Subjects
Details
- ISSN :
- 14642662 and 14681293
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- HIV Medicine
- Accession number :
- edsair.doi.dedup.....09497cabdf445894c44aa3e9eddcc0d7